BFRG 株価分析 — Bullfrog Ai Holdings, Inc. Common Stock (Healthcare >> Health Information Services)
BFRG に関するよくある質問
BFRGのROE(自己資本利益率)は?
Bullfrog Ai Holdings, Inc. Common StockのROEは-124.29%です。
BFRGの配当利回りは?
Bullfrog Ai Holdings, Inc. Common Stockの配当利回りは0.00%です。
BFRGの品質スコア(Quality Score)は?
当社のAIはBFRGの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BFRGは今が買い時ですか?
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BFRGはどのセクターに属しますか?
Bullfrog Ai Holdings, Inc. Common StockはHealthcare >> Health Information Servicesセクターに分類されます(NASDAQ市場)
BFRG AI Analysis Summary
Our AI summary for BFRG: Bullfrog Ai Holdings, Inc. Common Stock (NASDAQ), Healthcare >> Health Information Services sector. The stock currently trades at a P/E of 0.00, ROE of -124.29%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.62
Price
0.00
(0.57%)
Day Change
|
|
|---|
BFRG, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
38% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.62 |
| PBV / Sector |
2.34 / 6.46
|
| Earning Per Share | -0.33 |
| PE / Sector |
N/A / 45.42
|
| PEG or PE/Growth / Sector |
N/A / -0.35
|
| Average 1M Daily Value |
0.10 M
GREAT
|
| Average 1W Daily Value |
0.12 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:42 |
| Symbol | BFRG |
| Name | BULLFROG AI HOLDINGS, INC. COMMON STOCK |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 18.54 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11.45 / 4,132.50 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 325 Ellington Boulevard, Gaithersburg, MD, United States, 20878
Phone: 240 658 6710
Website: https://www.bullfrogai.com
Description: Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
Google